Jeevan Scientific Technology Ltd (538837) — Multibagger Analysis

Executive Summary & Catalyst Evaluation: On August 1, 2026, Jeevan Scientific received CDSCO approval to expand bed capacity from 138 to 164 beds (+18.8%) at its Hyderabad Bioavailability/Bioequivalence (BA/BE) center. This regulatory clearance directly follows a successful zero-483 USFDA inspection on July 24, 2026, establishing compliance credibility. ### Financial Uplift Math: TTM Revenue stands at Rs 61.5 Cr. An 18.8% bed expansion provides physical capacity for ~Rs 11.5 Cr in additional annual revenue. Assuming a realistic 60% capacity utilization ramp in Year 1, Year 1 revenue uplift is estimated at 12% (~Rs 7.4 Cr), achieving steady-state 18.8% uplift (~Rs 11.5 Cr) in Year 2. With H2 FY26 demonstrating margin recovery (OPM ~20-22%), operating leverage on incremental beds is expected to generate ~35% steady-state EPS uplift over FY26 base EPS of Rs 0.58. ### Governance & Mandate Caps: Promoter shareholding fell sharply from 38.05% in Dec 2025 to 30.25% in Mar 2026. Under strict research guardrails, a promoter holding below 35% automatically caps the multibagger verdict at POSSIBLE and confidence at <= 0.50. ### Scenario Calibration: Base Case (+35% upside over 12-24m) assumes steady bed utilization ramp and annualized PAT of Rs 8-9 Cr. Bull Case (+75% upside) reflects full bed utilization and P/E re-rating following USFDA validation. Bear Case (-30% downside) accounts for potential further promoter selling or delayed study sign-ups.